文献速递消化系统肿瘤

利用O6-甲基鸟嘌呤-DNA甲基转移酶蛋白质组学分析优化转移性结直肠癌患者替莫唑胺治疗的选择

Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
PubMed 文献 · Eur J Cancer · 2018-12-19

该研究对三项II期替莫唑胺试验中MGMT甲基化转移性结直肠癌患者的41份存档肿瘤样本进行三种MGMT检测方法比较,发现质谱法评估的低/阴性MGMT蛋白表达者无进展生存期较长(3.7 vs 1.8个月;HR=0.50,P=0.014),总生存期结果相似但未达统计学显著(8.7 vs 7.4个月;HR=0.55,P=0.077)。

要点

  • 质谱法检测低/阴性MGMT蛋白表达者接受替莫唑胺的PFS显著优于高表达者(3.7 vs 1.8个月;HR=0.50,P=0.014)。
  • 质谱法评估的总生存期差异未达统计学显著(8.7 vs 7.4个月;HR=0.55,P=0.077)。
  • 甲基化BEAMing法和RNA-seq法评估的MGMT状态与生存无显著关联。

核心结论

  • 定量蛋白质组学分析MGMT可能有助于优化适合单药替莫唑胺挽救治疗的患者选择。

研究设计与样本

  • 回顾性分析三项II期替莫唑胺试验中MGMT甲基化转移性结直肠癌患者的41份存档肿瘤样本,按质谱法、PCR/甲基化BEAMing法和RNA-seq法三种方法评估MGMT状态。

主要发现

  • 41例患者中9例对替莫唑胺有应答。
  • 质谱法判定可能应答者的总缓解率为50%(9/18),甲基化BEAMing法为50%(6/12),RNA-seq法为35%(8/23)。
  • 质谱法低/阴性MGMT蛋白表达者的无进展生存期长于高表达者(3.7 vs 1.8个月;HR=0.50,P=0.014)。
  • 质谱法低/阴性MGMT蛋白表达者与高表达者的总生存期结果相似但未达统计学显著(8.7 vs 7.4个月;HR=0.55,P=0.077)。
  • 甲基化BEAMing法高甲基化与低甲基化比较:无进展生存期HR=0.783,P=0.46;总生存期HR=0.591,P=0.126。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT) is a validated predictor of benefit from temozolomide (TMZ) in glioblastoma. However, only 10% of patients with MGMT-methylated metastatic colorectal cancer (mCRC) respond to TMZ. METHODS: Archived tumour samples (N = 41) from three phase II TMZ trials carried out in MGMT-methylated mCRC (assessed by methylation-specific polymerase chain reaction [PCR]) were stratified by MGMT status as assessed by three different methods: mass spectrometry, PCR/methyl-BEAMing and RNA-seq. The performance of each method was assessed in relation to overall response rate, progression-free survival (PFS) and overall survival (OS). RESULTS: Overall, 9 of 41 patients responded to TMZ. Overall response rates were 50% (9/18), 50% (6/12) and 35% (8/23) among patients determined likely to respond to TMZ by mass spectrometry, methyl-BEAMing and RNA-seq, respectively. Low/negative MGMT protein expressors by mass spectrometry had longer PFS than high MGMT expressors (3.7 vs 1.8 months; HR = 0.50, P = 0.014). Results for OS were similar but statistically non-significant (8.7 vs. 7.4 months; HR = 0.55, P = 0.077). No significant association between survival and MGMT status by methyl-BEAMing or RNA-seq could be demonstrated as comparable subgroups survival could not be confirmed/excluded. Specifically, the association of high versus low methyl-BEAMing MGMT hypermethylation with survival was HR = 0.783, P = 0.46 for PFS and 0.591, P = 0.126 for OS, while association of low versus high RNA-seq MGMT level with survival was HR = 0.697, P = 0.159 for PFS and HR = 0.697, P = 0.266 for OS. CONCLUSIONS: Quantitative proteomic analysis of MGMT may be useful for refining the selection of patients eligible for salvage treatment with single-agent TMZ.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schwartz S, Szeto C, Tian Y, et al. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. Eur J Cancer. 2018. PMID: 30579113. doi:10.1016/j.ejca.2018.11.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。